Pharma Company Giving 7920% Returns; Great Results, This Stock Is About To Jump
In the last 9 months, he invested pharma company Newland Labs share that has given 200 percent returns to investors. The share has given 7920% return so far.
On Monday, shares of Newland Lab reached the level of Rs 6540. The 52-week high level of Newland Lab share is Rs 6914 while the 52-week low is Rs 1362.65
Shares of Newland Lab, with a market cap of around Rs 8273 crore, has given a return of 4.51% to the investors in the last 5 days, while in the last 1 month, it has given a return of 15.88% and in the last 6 months the shares have given a return of 61.67% to the investors.
The price of Newland Lab has increased from the level of Rs 4105 to Rs 6540. The price has strengthened and touched the level of 6914. Recently Newland Lab has released excellent quarterly results.
On February 13, 2023, shares of Newland Lab were at the level of Rs 1412 from where investors got a bumper return of 381 percent.
The shares of Newland Lab, invested by veteran stock market investor gave a bumper return of 1062 percent to the investors from the level of Rs 584 on February 15, 2019.
During the Corona crisis, on March 27, 2020, Newland Lab’s share was at a low of Rs 261, from where investors’ capital has increased 25 times. Expert stock market investor has a significant stake in this company.
The investor has made no change in his stake in Newland Lab in the December quarter. His stake in the company is 3.01 percent. He holds four lakh shares of Newland Lab and his holding value is Rs 271 crore.
He held a 3.3 percent stake in Newland Lab in the June quarter, which he reduced to 3.1 percent in the September quarter. He has a long-term stake in Newland Labs. He held a 3.1 percent stake in Newland Lab in the December 2021 quarter.
About Neuland Laboratories Ltd
Neuland Laboratories Limited is an Indian firm. The company is a service provider for domestic and international markets.
It produces active pharmaceutical substances (APIs) in addition to being a complete solution provider to the chemistry requirements of the pharmaceutical industry.
The company offers solutions for the entire range of chemical requirements of the pharmaceutical industry starting from the creation of library compounds to the supply of NCEs along with advanced intermediates at different stages of the clinical cycle, to commercial launch.
The company operates two lines of business that comprise generic drugs (GDS) and custom-designed Manufacturing Solutions (CMS).
The company’s services and products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol along with Custom Manufacturing Services.
Fundamental Analysis of Neuland Laboratories Ltd
| Market Cap | ₹ 8,273 Cr. |
| Current Price | ₹ 6,540 |
| 52-wk High | ₹ 6,914 |
| 52-wk Low | ₹ 1,362 |
| Stock P/E | 26.46 |
| Book Value | ₹ 883 |
| Dividend | 0.15 % |
| ROCE | 20.8 % |
| ROE | 17.9 % |
| Face Value | ₹ 10.0 |
| P/B Value | 7.67 |
| OPM | 30.1 % |
| EPS | ₹ 247 |
| Debt | ₹ 101 Cr. |
| Debt to Equity | 0.09 |
Neuland Laboratories Share Price Target 2024 To 2030
| Year | 1st Target | 2nd Target |
| 2024 | ₹6500 | ₹6947 |
| 2025 | ₹7000 | ₹7215 |
| 2026 | ₹7315 | ₹7658 |
| 2027 | ₹7748 | ₹7985 |
| 2028 | ₹8000 | ₹8325 |
| 2029 | ₹8658 | ₹8894 |
| 2030 | ₹9000 | ₹9325 |
Neuland Laboratories Shareholding Pattern
| Promoters Holding | |
| Dec 2022 | 36.14% |
| Mar 2023 | 36.14% |
| June 2023 | 36.03% |
| Sept 2023 | 35.97% |
| Dec 2023 | 32.80% |
| FII Holding | |
| Dec 2022 | 17.68% |
| Mar 2023 | 17.70% |
| June 2023 | 18.14% |
| Sept 2023 | 21.57% |
| Dec 2023 | 22.69% |
| DII Holding | |
| Dec 2022 | 6.54% |
| Mar 2023 | 7.10% |
| June 2023 | 6.76% |
| Sept 2023 | 6.99% |
| Dec 2023 | 6.02% |
| Govt. Holding | |
| Dec 2022 | 0.46% |
| Mar 2023 | 0.40% |
| June 2023 | 0.40% |
| Sept 2023 | 0.40% |
| Dec 2023 | 0.40% |
| Public Holding | |
| Dec 2022 | 39.15% |
| Mar 2023 | 38.22% |
| June 2023 | 36.62% |
| Sept 2023 | 35.08% |
| Dec 2023 | 38.10% |
Neuland Laboratories Share: Last 5 Years’ Financial Condition
To better understand how the market is performing, let’s look at the outlook of this share in the previous years.
However, investors should be aware of the risks and the market conditions before making any investment decision.
Last 5 Years’ Sales:
| 2019 | ₹ 667 Cr |
| 2020 | ₹ 763 Cr |
| 2021 | ₹ 937 Cr |
| 2022 | ₹ 951 Cr |
| 2023 | ₹ 1,581 Cr |
Last 5 Years’ Net Profit:
| 2019 | ₹ 16 Cr |
| 2020 | ₹ 16 Cr |
| 2021 | ₹ 81 Cr |
| 2022 | ₹ 64 Cr |
| 2023 | ₹ 317 Cr |
Last 5 Years’ Debt-To-Equity Ratio:
| 2019 | 0.3 |
| 2020 | 0.35 |
| 2021 | 0.18 |
| 2022 | 0.28 |
| 2023 | 0.12 |
Last 10 Years’ Profit Growth:
| 10 Years: | 29% |
| 5 Years: | 68% |
| 3 Years: | 117% |
| Current Year: | 215% |
Last 10 years’ Return on Equity (ROE):
| 10 Years: | 9% |
| 5 Years: | 9% |
| 3 Years: | 12% |
| Last Year: | 18% |
Sales Growth Over 10 Years:
| 10 Years: | 10% |
| 5 Years: | 18% |
| 3 Years: | 16% |
| Current Year: | 52% |
Conclusion
This article is a complete guide about Neuland Laboratories Ltd Share. This information and forecasts are based on our research, company fundamentals, history, experiences, and technical analyses.
Also, We have discussed the share’s prospects and growth potential in detail.
This information will help you in your further investment.
If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.
If you have any further queries, please comment below. We will be happy to answer all your questions.
If you like this information, share the article with as many people as possible.
